Performance Evaluation of Noninvasive Prenatal Testing in Screening Chromosome Disorders: A Single-Center Observational Study of 15,304 Consecutive Cases in China
Qiang Ye,Guoping Huang,Qin Hu,Qin Man,Xiaoying Hao,Liangyan Liu,Qiang Zhong,Zhao Jin
DOI: https://doi.org/10.2147/ijwh.s455778
2024-03-30
International Journal of Women s Health
Abstract:Qiang Ye, 1 Guoping Huang, 1 Qin Hu, 1 Qin Man, 2 Xiaoying Hao, 3 Liangyan Liu, 4 Qiang Zhong, 1 Zhao Jin 2 1 Department of Clinical Laboratory, West China Second University Hospital, Southern Sichuan Women's and Children's Hospital, Zigong, Sichuan, 643000, People's Republic of China; 2 Department of Prenatal Diagnosis Center, West China Second University Hospital, Southern Sichuan Women's and Children's Hospital, Zigong, Sichuan, 643000, People's Republic of China; 3 Department of Ultrasound, West China Second University Hospital, Southern Sichuan Women's and Children's Hospital, Zigong, Sichuan, 643000, People's Republic of China; 4 Department of Obstetrics, West China Second University Hospital, Southern Sichuan Women's and Children's Hospital, Zigong, Sichuan, 643000, People's Republic of China Correspondence: Zhao Jin, Department of Prenatal Diagnosis Center, West China Second University Hospital, Southern Sichuan Women's and Children's Hospital, No. 49 Da Huang Tong Road, Da'an District, Zigong, Sichuan, 643000, People's Republic of China, Tel +86-13990094008, Email Objective: This study was to evaluate the performance of noninvasive prenatal testing (NIPT) in detecting fetal chromosome disorders in pregnant women. Methods: From October 1st, 2017, to December 31th, 2022, a total of 15,304 plasma cell free DNA-NIPT samples were collected for fetal chromosome disorders screening. The results of NIPT were validated by confirmatory invasive testing or clinical outcome follow-up. Further, NIPT performance between low-risk and high-risk groups, as well as singleton pregnancy and twin pregnancy groups was compared. Besides, analysis of 111 false-positive cases was performed. Results: Totally, NIPT was performed on 15,086 eligible venous blood samples, of which 179 (1.19%) showed positive NIPT results and 68 were further validated to be true positive samples via confirmatory invasive testing or follow-up of clinical outcomes. For common chromosome aneuploidies, sex chromosome abnormalities (SCA) and other chromosomal aneuploidies, the detection sensitivities of NIPT were all 100%, the specificities were 99.87%, 99.70%, and 99.68% and the positive predictive values (PPVs) were 65.45%, 31.82%, and 10.91%, respectively. No statistically significant variance in detection performance was observed among 2987 high-risk and 12,099 low-risk subjects, as well as singleton and twin pregnancy subjects. The concentration of cell-free fetal DNA of 111 false-positive cases ranged from 5.5% to 33.7%, which was higher than the minimum requirement of NIPT. Conclusion: With stringent protocol, NIPT shows high sensitivity and specificity for detecting fetal chromosome disorders in a large-scale clinical service, helping improving overall pregnancy management. Keywords: noninvasive prenatal testing, fetal chromosome disorders, high risk, twin pregnancy, performance evaluation Fetal chromosome disorders are generally defined as syndromes caused by abnormal chromosome number or chromosome structure, leading to a complex and diverse range of symptoms such as intellectual disability, developmental delay, and malformations. Certain medications, treatments or rehabilitative methods can relieve the patient's condition or suffering, but are not curative. 1 Chromosome aneuploidy is the most common type of fetal chromosome disorders, among which trisomies (T) 21, 18, 13 are the most typical, and the incidence of these trisomies is relatively high, accounting for about 0.2% of all full-term pregnancies. 2 Sex chromosome abnormalities (SCA), such as 47, XYY (Fernando syndrome), 47, XXX (Hyperemesis), 47, XXY (Klinefelter syndrome), 45, X (Turner syndrome), are a chromosomal disorder with an abnormal number of sex chromosomes, with an incidence of 1 in 200 to 1 in 400 live births and a prenatal diagnosis incidence of up to 1 in 435. Most of these patients are detected by karyotype analysis due to abnormal pubertal development, which may miss the best time to use the corresponding hormone treatment and lead to unremarkable treatment effect. In addition, with the development of treatment technology, other types of chromosomal disorders, such as other chromosome abnormalities and chromosome copy number variants (CNVs), are also attracting increasing attention. 3 Prenatal screening is a vital tool to detect fetal chromosomal disorders and reduce the birth of fetuses with birth defects. Traditional screening and detection of fetal aneuploidy depends on biochemical detection and ultrasonic detection, and the detection rate is 50–95%, 4 which is unstable and unsatisfactory, leading to many meaningless inv -Abstract Truncated-
obstetrics & gynecology